To investigate the efficacy of tocilizumab in RA patients with moderate disease activity under biologic therapy

To investigate the efficacy of tocilizumab in RA patients with moderate disease activity under biologic therapy - To investigate the efficacy of tocilizumab in RA patients with moderate disease activity

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010033

Enrollment

Registered

2013-02-14

Start date

2013-02-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

Tocilizumab (8 mg/kg of body weight) is to be infused every 4 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients between 20 and 75 years old 2)Patients with rheumatoid arthritis 3)Patients with low to moderate activity activity under more than 24 weeks of anti-tumour necrosis factor biologic therapy 4)Moderate disease activity by SDAI 5)The patient by whom consent is got in written form about participation of the final examination

Exclusion criteria

Exclusion criteria: 1)Patients who have serious infection 2)Patients who have history of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies 3)Patients who have history of a malignant tumor, or who have malignant tumor 4)Patients who have serious cardiac disease or liver disease, renal damage 5)Pregnant women or women trying to get pregnant 6)Patients considered inappropriate judged by attending physicians

Design outcomes

Primary

Measure	Time frame
Low disease activity rate at 24 weeks (SDAI)	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026